title: Anti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinase.
abstract: beta-L-5-Iododioxolane uracil was shown to have potent anti-Epstein-Barr virus (EBV) activity (50% effective concentration = 0.03 microM) with low cytotoxicity (50% cytotoxic concentration = 1,000 microM). It exerts its antiviral activity by suppressing replicative EBV DNA and viral protein synthesis. This compound is phosphorylated in cells where the EBV is replicating but not in cells where the EBV is latent. EBV-specific thymidine kinase could phosphorylate beta-L-5-iododioxolane uracil to the monophosphate metabolite. The K(m) of beta-L-5-iododioxolane uracil with EBV thymidine kinase was estimated to be 5.5 microM, which is similar to that obtained with thymidine but about fivefold higher than that obtained with 2' fluoro-5-methyl-beta-L-arabinofuranosyl uracil, the first L-nucleoside analogue discovered to have anti-EBV activity. The relative V(max) is seven times higher than that of thymidine. The anti-EBV activity of beta-L-5-iododioxolane uracil and its intracellular phosphorylation could be inhibited by 5'-ethynylthymidine, a potent EBV thymidine kinase inhibitor. The present study suggests that beta-L-5-iododioxolane uracil exerts its action after phosphorylation; therefore, EBV thymidine kinase is critical for the antiviral action of this drug.
authors.affiliation: Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
authors.forename: T
authors.initials: T
authors.lastname: Kira
authors.forename: S P
authors.initials: SP
authors.lastname: Grill
authors.forename: G E
authors.initials: GE
authors.lastname: Dutschman
authors.forename: J S
authors.initials: JS
authors.lastname: Lin
authors.forename: F
authors.initials: F
authors.lastname: Qu
authors.forename: Y
authors.initials: Y
authors.lastname: Choi
authors.forename: C K
authors.initials: CK
authors.lastname: Chu
authors.forename: Y C
authors.initials: YC
authors.lastname: Cheng
mesh_terms: D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology*; D004148:Dioxolanes / Q000378:metabolism / Q000494:pharmacology*; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004854:Herpesvirus 4, Human / Q000187:drug effects*; D006801:Humans; D013379:Substrate Specificity; D013936:Thymidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D013937:Thymidine Kinase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D014498:Uracil / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects
chemical_list: C419688:5-iododioxolane uracil; D000998:Antiviral Agents; D004148:Dioxolanes; D004791:Enzyme Inhibitors; D014498:Uracil; C052263:5'-ethynylthymidine; D013937:Thymidine Kinase; D013936:Thymidine